Neurocrine Biosciences shares are trading higher after falling Wednesday despite its Phase 2 study of NBI-1117568 in schizophrenia meeting its primary endpoint. Piper Sandler upgraded the stock from Neutral to Overweight on Thursday.
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences shares rose after a Phase 2 study of NBI-1117568 in schizophrenia met its primary endpoint. Piper Sandler upgraded the stock from Neutral to Overweight.
August 29, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences shares increased after a successful Phase 2 study in schizophrenia and an upgrade from Piper Sandler to Overweight.
The successful Phase 2 study result is a positive development for Neurocrine Biosciences, indicating potential future success in treating schizophrenia. Additionally, the upgrade from Piper Sandler to Overweight suggests increased confidence from analysts, likely boosting investor sentiment and driving the stock price higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100